Clinical Challenges

Intraperitoneal Chemotherapy for Ovarian Cancer

Paula Anastasia

chemotherapy, ovarian neoplasms
ONF 2012, 39(4), 346-349. DOI: 10.1188/12.ONF.346-349

Ovarian cancer remains an uncommon cancer compared to other female malignancies, such as breast, lung, and colon cancer. However, ovarian cancer is the leading cause of death among all gynecologic malignancies and the second most prevalent of the reproductive cancers (Siegel, Naishadham, & Jemal, 2012). According to the National Comprehensive Cancer Network ([NCCN], 2012b), the standard of care for advanced epithelial ovarian cancer (EOC) consists of an IV platinum and taxane-based chemotherapy for 6-8 cycles, or combination IV and intraperitoneal (IP) chemotherapy for patients with stage II or III cancer who have had optimally debulked (less than 1 cm residual) surgery (see Figure 1).

Jump to a section

    References

    Alberts, D.S., Liu, P.Y., Hannigan, E.T., O'Toole, R., Williams, S., Young, J.A., … DuBeshler, B. (1996). Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New England Journal of Medicine, 335, 1950-1955. doi:10.1056/NEJM199612263352603
    Almadrones, L. (2007). Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer. Clinical Journal of Oncology Nursing, 11, 211-216. doi:10.1188/07.CJON.211-216
    Anderson, N., & Hacker, E.D. (2008). Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer: A review of contributing factors. Clinical Journal of Oncology Nursing, 12, 445-454. doi:10.1188/08.CJON.445-454
    Armstrong, D.K., Bundy, B., Wenzel, L., Huang, H.Q., Baergan, R., Lele, S., & Burger, R.A. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine, 354, 34-43.
    Eisenhauer, E.A., ten Bokkel Huinink, W.W., Swenerton, K.D., Gianni, L., Myles, J., van der Burg, M.D., … Columbo, N. (1994). European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long-versus-short infusion. Journal of Clinical Oncology, 12, 2654-2666.
    Hydzik, C. (2007). Implementation of intraperitoneal chemotherapy for the treatment of ovarian cancer. Clinical Journal of Oncology Nursing, 11, 221-225. doi:10.1188/07.CJON.221-225
    Kiser, D., Greer, T.B., Wilmoth, M.C., Dmochowski, J., & Naumann, R.W. (2010). Peripheral neuropathy in patients with gynecologic cancer receiving chemotherapy: Patient reports and provider assessments. Oncology Nursing Forum, 37, 758-764. doi:10.1188/10.ONF.758-764
    Markman, M., Bundy, B.N., Alberts, D.S., Fowler, J.M., Clark-Pearson, D.L., Carson, L.F., … Sickel, J. (2001). Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage II ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 19, 1001-1007.
    Markman, M., & Walker, J.L. (2006). Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment. Journal of Clinical Oncology, 24, 988-994.
    National Cancer Institute. (2006). Abdominal chemotherapy for ovarian cancer improves survival. NCI Cancer Bulletin, 3(2), 1.
    National Comprehensive Cancer Network. (2012a). NCCN Clinical Practice Guidelines in Oncology: Antiemesis[v.1.2012]. Retrieved from http://www.nccn.org/professionals/physician_gls/PDF/antiemetics.pdf
    National Comprehensive Cancer Network. (2012b). NCCN Clinical Practice Guidelines in Oncology: Ovarian cancer[v.1.2012]. Retrieved from http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf
    Potter, K., & Held-Warmkessel, J. (2008). Intraperitoneal chemotherapy in women with ovarian cancer: Nursing care and considerations. Clinical Journal of Oncology Nursing, 12, 265-271. doi:10.1188/08.CJON.265-271
    Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 10-29. doi:10.3322/caac.20138/08
    Wenzel, L.B., Huang, H.Q., Armstrong, D.K., Walker, J.L., & Cella, D. (2007). Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: A Gynecologic Oncology Group study. Journal of Clinical Oncology, 25, 437-443.
    Alberts, D.S., Liu, P.Y., Hannigan, E.T., O'Toole, R., Williams, S., Young, J.A., … DuBeshler, B. (1996). Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New England Journal of Medicine, 335, 1950-1955. doi:10.1056/NEJM199612263352603
    Almadrones, L. (2007). Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer. Clinical Journal of Oncology Nursing, 11, 211-216. doi:10.1188/07.CJON.211-216
    Anderson, N., & Hacker, E.D. (2008). Fatigue in women receiving intraperi-toneal chemotherapy for ovarian cancer: A review of contributing factors. Clinical Journal of Oncology Nursing, 12, 445-454. doi:10.1188/08.CJON.445-454
    Armstrong, D.K., Bundy, B., Wenzel, L., Huang, H.Q., Baergan, R., Lele, S., & Burger, R.A. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine, 354, 34-43. doi:10.1056/NEJMoa052985
    Eisenhauer, E.A., ten Bokkel Huinink, W.W., Swenerton, K.D., Gianni, L., Myles, J., van der Burg, M.D., … Columbo, N. (1994). European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology, 12, 2654-2666.
    Markman, M., Bundy, B.N., Alberts, D.S., Fowler, J.M., Clark-Pearson, D.L., Carson, L.F., … Sickel, J. (2001). Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage II ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 19, 1001-1007.
    National Cancer Institute. (2012). Epithelial ovarian cancer: Epithelial cancer. Retrieved from www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/HealthProfessional/page5#Section_484
    National Comprehensive Cancer Network. (2012). NCCN Clinical Practice Guidelines in Oncology: Ovarian cancer. Retrieved from http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf
    Potter, K., & Held-Warmkessel, J. (2008). Intraperitoneal chemotherapy in women with ovarian cancer: Nursing care and considerations. Clinical Journal of Oncology Nursing, 12, 265-271. doi:10.1188/08.CJON.265-271